NASD · Healthcare · Biotechnology · USA
iBio Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
iBio is a clinical-stage biotechnology company developing precision antibodies using artificial intelligence for obesity, cardiometabolic, and cardiopulmonary diseases. The company leverages its AI Drug Discovery Platform to identify novel biologics targeting unmet medical needs. iBio has advanced IBIO-600 into human clinical trials and is developing additional therapeutic candidates in preclinical stages.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the iBio Inc stock.
Undervalued: intrinsic value $1.12 per share, market price $0.75, margin of safety 33.1% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $1.12; the price of $0.75 is 33% below that value.
11 more in this industry show a wider margin of safety.
IBIO is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.12; the price of $0.75 is 33% below that value.
$1.12 per share (as of the 2026-11-17 close), against a market price of $0.75. That is a margin of safety of 33.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.